– Career as a veteran drug developer spans patient care, FDA and biopharma –
– Dr Goodman to lead Exelixis expansion on the east coast –
ALAMEDA, California, January 04, 2022– (BUSINESS WIRE) – Exelixis, Inc. (Nasdaq: EXEL) today announced the appointment of Vicki L. Goodman, MD, as Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer . Dr Goodman has over 20 years of oncology experience as a leader in drug development with global biopharmaceutical organizations, regulators and clinicians. She joins Exelixis from Merck, where she held the position of Vice-President, responsible for clinical research and therapeutic area, late stage oncology; his previous mandates in the biopharmaceutical industry include clinical development leadership roles at Bristol Myers Squibb and GlaxoSmithKline. Dr Goodman Joins Exelixis as Company Continues to Maximize Clinical Potential of CABOMETYX® (cabozantinib), its global oncology franchise, while rapidly advancing its portfolio of promising small molecule and experimental biologics to treat cancer.
“With her track record of successfully developing targeted therapies and immunotherapies at a global biopharmaceutical level, as well as her experience as an FDA reviewer and hematologist-oncologist, Dr. Vicki Goodman is uniquely positioned to be the next Director. Medical Exelixis, ”said Michael M. Morrissey, Ph.D., President and CEO, Exelixis. “We are delighted to welcome Dr. Goodman to Exelixis as we execute the ongoing CABOMETYX Phase 3 pivotal trials, accelerate late-stage clinical development of XL092, our next-generation oral tyrosine kinase inhibitor,” and advance an exciting clinical pipeline of small molecules and biologics, including XB002, our first antibody-drug conjugate. “
As CMO of Exelixis, Dr Goodman will lead the clinical development and medical business functions of Exelixis, leveraging experience gained throughout his varied career. At Merck (2020-2021), she was responsible for overseeing key elements of the company’s end-stage development portfolio, including KEYTRUDA® (pembrolizumab) and other advanced stage actives, in chest malignancies, head and neck cancers, breast and gynecological cancers and hematology. Prior to joining Merck, Dr Goodman worked at Bristol Myers Squibb for five years, during which time she was a member of the company’s oncology leadership team. Initially, as Vice President Development Lead (2015-2017), she led the cross-functional team developing OPDIVO® (nivolumab) / YERVOY® (ipilimumab) for melanoma and genitourinary tumors, which included collaboration with Exelixis on the design of the CheckMate -9ER trial. In 2017, she was promoted to Vice President and Head of New Asset Development Teams, a role that included overseeing teams advancing a variety of assets between proof of concept and approval. Previously, from 2007 to 2015, Dr Goodman held positions of increasing responsibility at GlaxoSmithKline (GSK), including as Project Physician for Dabrafenib from Phase 1 expansion to regulatory approval, as well as Senior Physician in the Cancer Epigenetics Unit at GSK, where she was responsible for the development strategy and clinical oversight of several assets initially entering clinical development.
“With a global oncology franchise in CABOMETYX, a growing clinical pipeline of new small molecules and biotherapeutics – including the company’s first antibody-drug conjugate – and ambitious plans to research new mechanisms, treatment modalities and disease contexts,” Exelixis is at an inflection point, “said Dr. Goodman.” I am delighted to use my extensive experience in drug development and regulatory affairs, as well as my clinical training, to lead the talented Exelixis product development and medical business teams move further forward in the company’s mission to help cancer patients recover stronger and live longer. I am also deeply honored to succeed to Dr Gisela M. Schwab, a pioneering clinical development and biopharmaceutical professional, in the role of Chief Medica l Officer.
Dr. Goodman will be based in the greater Philadelphia area. As part of her role overseeing the company’s product development operations, she will play a leadership role in building a new Exelixis team that will expand the company’s development activities on the east coast. Exelixis’ presence on the East Coast will complement the company’s strong and growing West Coast development team and allow the company to move even faster on behalf of patients, including laying the groundwork for a potential future growth outside the United States. Founded in Cambridge, Massachusetts, in 1994, Exelixis has been established in California since 1997 and will continue to maintain and expand its global headquarters and oncology drug development activities in Alameda. Exelixis will share more information on its plans for the east coast as they evolve over the course of this year.
Prior to entering the biopharmaceutical industry, from 2004 to 2007, Dr. Goodman was a physician in the Division of Drug Oncology Products, which was part of the Center for Drug Evaluation and Research of the United States Food and Drug Administration. Prior to that, from 2001-2004, she obtained a Clinical Fellowship in Hematology and Medical Oncology at the University of Michigan, Ann Arbor, where she also completed her internship and residency. Dr. Goodman received her MD from Albert Einstein College of Medicine and her BA in Biochemistry with Distinction from Rutgers University.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful oncology-focused biotechnology company working to accelerate the discovery, development and commercialization of new drugs for difficult-to-treat cancers. . Following early work on the genetics of model systems, we established a broad drug discovery and development platform that has served as the basis for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we’ve partnered with leading pharmaceutical companies to bring these important drugs to patients around the world. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business in order to maximize the potential of our pipeline. We complement our existing therapeutic assets with targeted business development and in-house drug discovery activities, all to deliver the next generation of Exelixis drugs and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 Index, which measures the performance of profitable mid-size companies. For more information on Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
This press release contains forward-looking statements, including, without limitation, statements relating to: Exelixis’ potential to accelerate the late-stage development of XL092 and to advance an exciting clinical pipeline of small molecules and Organic Products ; Exelixis ‘plans to expand its development activities on the East Coast, as well as prepare for potential future growth outside the United States, and Exelixis’ intention to share more information on these plans during 2022; and Exelixis’ plans to reinvest in its businesses to maximize the potential of the company’s pipeline, including through targeted business development and internal drug discovery activities. Any statement that refers to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based on Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and timing of events could differ materially from those anticipated in forward-looking statements due to these risks and uncertainties, which include, but are not limited to: the complexities and unpredictability of the review and approval processes regulatory in the United States and elsewhere; Exelixis’ continued compliance with applicable legal and regulatory requirements; the potential failure of cabozantinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and / or efficacy in clinical trials; uncertainties inherent in the product development process; the costs of carrying out clinical trials; Exelixis’ dependence on third party suppliers for the development, manufacture and supply of its products and product candidates; Exelixis’ ability to protect its intellectual property rights; competition in the market, including the possibility for competitors to obtain approval of generic versions of CABOMETYX; changes in economic and business conditions, including as a result of the COVID-19 pandemic; and other factors affecting Exelixis and its development programs discussed under the heading “Risk Factors” in Exelixis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2021, and in future Exelixis documents with the second. All forward-looking statements contained in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis does not undertake to update or revise the forward-looking statements contained herein, unless the law requires it.
Exelixis, the Exelixis logo, CABOMETYX, and COMETRIQ are U.S. registered trademarks of Exelixis. COTELLIC is a registered trademark of Genentech, Inc.
MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.
OPDIVO® and YERVOY® are registered trademarks of Bristol Myers Squibb.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220104005214/en/
Executive Vice President, Public Affairs and
Exelixis media contact:
For Exelixis, Inc.